Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Epinephrine for Systemic Allergic Reactions
NCT07038746Phase 1Recruiting
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of epinephrine in anaphylaxis and Hypersensitivity. Primary endpoints: Time to resolution of systemic symptoms at 60 minutes and Time to complete resolution of systemic symptoms at 60 minutes. Started Aug 2025; status: recruiting.
02
Drugs
epinephrine
03
Conditions
anaphylaxisHypersensitivity
Beyond the preview
Go deeper on NCT07038746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07038746.